Literature DB >> 27495910

[Short version of the German S3 guideline for bladder cancer].

M Retz1, J E Gschwend2, P Maisch2.   

Abstract

Urinary bladder cancer is the second most common cancer of the urogenital system. The Guideline Program in Oncology (Leitlinienprogramm Onkologie) of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF), the German Cancer Society (Deutsche Krebsgesellschaft) and the German Cancer Aid (Deutsche Krebshilfe) as well as 31 different medical societies have developed the first interdisciplinary, evidence-based German guideline for bladder cancer. This short version presents the resulting series of diagnostic and therapeutic recommendations which were based on a systematic literature search and approved by a team of bladder cancer experts. The full version is available under http://leitlinienprogramm-onkologie.de/ .

Entities:  

Keywords:  Cystectomy, radical; Grading of recommendations; Guideline program; Level of evidence; Meta-analysis

Mesh：

Substances：

Year:  2016        PMID： 27495910     DOI： 10.1007/s00120-016-0195-1

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  48 in total

1.  Need for intravenous urography in patients with primary transitional carcinoma of the bladder?

Authors:  F Herranz-Amo; J M Diez-Cordero; F Verdú-Tartajo; G Bueno-Chomón; F Leal-Hernández; A Bielsa-Carrillo
Journal:  Eur Urol       Date:  1999-09       Impact factor: 20.096

2.  Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.

Authors:  F Millán-Rodríguez; G Chéchile-Toniolo; J Salvador-Bayarri; J Huguet-Pérez; J Vicente-Rodríguez
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

3.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

Authors:  A Böhle; D Jocham; P R Bock
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

4.  Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.

Authors:  Truls Gårdmark; Staffan Jahnson; Rolf Wahlquist; Hans Wijkström; Per-Uno Malmström
Journal:  BJU Int       Date:  2007-01-22       Impact factor: 5.588

Review 5.  Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent.

Authors:  Lars Weisbach; Roland Dahlem; Giuseppe Simone; Jens Hansen; Armin Soave; Oliver Engel; Felix K Chun; Shahrokh F Shariat; Margit Fisch; Michael Rink
Journal:  Int Urol Nephrol       Date:  2013-07-25       Impact factor: 2.370

Review 6.  Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Authors:  Michael Rink; Marko Babjuk; James W F Catto; Patrice Jichlinski; Shahrokh F Shariat; Arnulf Stenzl; Herbert Stepp; Dirk Zaak; J Alfred Witjes
Journal:  Eur Urol       Date:  2013-07-19       Impact factor: 20.096

7.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

8.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

Review 9.  Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.

Authors:  Lily P H Yang
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

10.  A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.

Authors:  G M Mead; M Russell; P Clark; S J Harland; P G Harper; R Cowan; J T Roberts; B M Uscinska; G O Griffiths; M K Parmar
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640
View more
  1 in total

1.  Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction.

Authors:  Fuguang Zhao; Olesya Vakhrusheva; Sascha D Markowitsch; Kimberly S Slade; Igor Tsaur; Jindrich Cinatl; Martin Michaelis; Thomas Efferth; Axel Haferkamp; Eva Juengel
Journal:  Cells       Date:  2020-12-09       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.